Theravectys makes two appointments to strengthen executive committee

Hires a Head of Clinical Development and a Head of Strategy and Business Development

French biotechnology firm Theravectys, which specialises in the development of vaccines based on lentiviral vector technology, has appointed Paul Gineste as Head of Clinical Development and Pierre D'Epenoux as Head of Strategy and Business Development.

Gineste was formerly Director of Clinical Studies at AB Science and will head clinical development at Theravecyts to bring in-house vaccine candidates into the clinics.

D'Epenoux, formerly VP of Strategy and Business Development Europe at Sanofi, will be responsible for the firm's strategic planning as well as establishing alliances with leading research institutes and global strategic partners.

You may also like